Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ramm Pharma (RAMM) Stock Price & Analysis

1 Followers

RAMM Stock Chart & Stats

CA$0.02CA$0.00(0.00%)
At close: 4:00 PM EST
C$0.01C$0.0125C$0.015Aug 21Sep 16Sep 29Oct 19Oct 29Nov 9
Day’s Range
CAD 0.02 - CAD 0.02
52-Week Range
CAD 0.01 - CAD 0.25
Previous Close
CAD 0.02
Volume
N/A
Average Volume (3M)
19.25K
Market Cap
CAD 1.79M
Enterprise Value
CAD 1.22M
Total Cash (Recent Filing)
CAD 147.13K
Total Debt (Recent Filing)
CAD 169.55K
Price to Earnings (P/E)
―
Beta
-3.72
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Debt-to-equity of about 0.01 indicates a very modest debt burden, reducing refinancing and balance-sheet stress compared with a highly leveraged structure. This gives management more financial flexibility to support operations and pursue product development, although it does not offset current losses.

Improved Gross Profitability

Gross profitability has improved versus earlier weaker years, providing evidence that product-level economics are not uniformly deteriorating. If maintained, this improvement could support future operating leverage as revenue recovers, although the pack stresses that gross profitability remains thin and volatile.

Defined Cannabinoid Product Platform

The company has a defined niche centered on cannabinoid-based pharmaceutical and nutraceutical formulations, with activities spanning development, regulatory and quality work, and branded-market distribution. That integrated scope can support a coherent commercialization platform over time, though performance remains execution-dependent.

Bears Say

Sharp Revenue Contraction

A 32.9% TTM revenue decline signals weakening commercial traction and reduces the scale available to absorb fixed operating costs. Persistent contraction could limit investment in product development, weaken market presence, and make a return to sustainable profitability more difficult over the next several quarters.

Persistent Unprofitability

Negative net and operating margins show that the current revenue base does not support the company’s cost structure. Continued losses can constrain strategic investment, erode shareholder capital, and increase dependence on improved demand or external funding before the business can achieve durable break-even performance.

Ongoing Cash Burn And Equity Erosion

Negative operating and free cash flow indicate that operations are consuming cash rather than funding the business internally. Combined with substantial equity erosion, this weakens financial resilience and may require external funding or remaining cash reserves to sustain operations until profitability improves.

Ramm Pharma News

RAMM FAQ

What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.79M.
When is Ramm Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ramm Pharma’s earnings last quarter?
Ramm Pharma released its earnings results on Sep 29, 2026. The company reported -C$0.007 earnings per share for the quarter.
Is Ramm Pharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Ramm Pharma reported an EPS of -C$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology